https://www.selleckchem.com/pr....oducts/AZD2281(Olapa
1% versus 10.3%; =0.22) for the IVCYC and MMF groups, respectively. Mortality rate for the IVCYC group was 5.5 per 10,000 person-days of follow-up compared to 1.5 per 10,000 person-days of follow-up for the MMF group ( =0.11), and there was no significant difference in infection-related adverse events between both groups. Estimated GFR at baseline was the only predictor of death (OR 1.0 [0.9-1.0]; =0.001). This study shows similar outcomes following induction treatment with MMF or IVCYC in patients with biopsy-proven prolifera
Aimer
Commentaire
Partagez
